Unity Biotechnology, Inc.

Unity Biotechnology, Inc. (UBX)

$3.01

+0.08

(+2.73%)

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Unity Biotechnology, Inc.

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 105.7%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.4% return, outperforming this stock by 119.8%

Performance

  • $2.89
    $3.05
    $3.01
    downward going graph

    3.99%

    Downside

    Day's Volatility :5.25%

    Upside

    1.31%

    downward going graph
  • $1.46
    $18.50
    $3.01
    downward going graph

    51.5%

    Downside

    52 Weeks Volatility :92.11%

    Upside

    83.73%

    downward going graph

Returns

PeriodUnity Biotechnology, Inc.Russel 2000Index (Russel 2000)
3 Months
-34.44%
-6.7%
-6.7%
6 Months
7.27%
-6.2%
-6.2%
1 Year
-62.66%
-5.1%
-5.1%
3 Years
-96.86%
26.9%
26.9%

Highlights

Market Capitalization
41.9M
Book Value
$4.08
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.22
Wall Street Target Price
7.4
Profit Margin
0.0%
Operating Margin TTM
-20363.56%
Return On Assets TTM
-26.5%
Return On Equity TTM
-94.91%
Revenue TTM
236.0K
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-35.2M
EBITDA
-46.2M
Diluted Eps TTM
-4.22
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.8
EPS Estimate Next Year
-3.55
EPS Estimate Current Quarter
-1.08
EPS Estimate Next Quarter
-1.12

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Unity Biotechnology, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 145.85%

Current $3.01
Target $7.40

Technicals Summary

Sell

Neutral

Buy

Unity Biotechnology, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Unity Biotechnology, Inc.
Unity Biotechnology, Inc.
34.09%
7.27%
-62.66%
-96.86%
-98.02%
Moderna, Inc.
Moderna, Inc.
-3.38%
-26.73%
-11.31%
107.29%
592.96%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.68%
-3.07%
9.61%
21.54%
142.61%
Seagen, Inc.
Seagen, Inc.
-2.59%
59.82%
42.99%
22.0%
220.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.71%
2.81%
21.09%
13.49%
111.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Unity Biotechnology, Inc.
Unity Biotechnology, Inc.
NA
NA
NA
-3.8
-0.95
-0.26
0.0
4.08
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Unity Biotechnology, Inc.
Unity Biotechnology, Inc.
Buy
$41.9M
-98.02%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
592.96%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
142.61%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
220.73%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
111.23%
26.53
35.4%

Institutional Holdings

  • ARCH VENTURE CORP

    7.00%
  • FMR Inc

    5.31%
  • Vanguard Group Inc

    3.65%
  • UBS O'Connor LLC

    1.48%
  • Mayo Clinic

    1.09%
  • Acadian Asset Management LLC

    0.73%

Corporate Announcements

  • Unity Biotechnology, Inc. Earnings

    Unity Biotechnology, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

Organization
Unity Biotechnology, Inc.
Employees
31
CEO
Dr. Anirvan Ghosh Ph.D.
Industry
Health Technology

FAQs